Also In The News:
UCLan awarded funding to help small businesses
Newton Heath to benefit from investment and improvements
Northwest businesses investigate Olympic opportunities
Burnley business park 'is flourishing'
Personal care giant invests in northwest site
Liverpool firm receives investment for internet services
Manchester University secures funding for business skills training
NWDA announces investment to help region's businesses
Manchester scientists study new chemotherapy drugs
01/08/2008
Dr Stephen Taylor and Karen Gascoigne at the university's faculty of life sciences are studying anti-mitotic drugs, which are used for ovarian and breast cancer.
Side effects of some cancer-busting drugs include permanent nerve damage and loss of sensation in the fingers.
Dr Taylor said that to cut out neurotoxicity, new anti-mitotics need to be generated and studied.
"Early clinical studies show that these drugs do not result in significant neurotoxicity. The big question now is whether they will have anti-tumour effects," he explained.
The findings so far have been are published in the journal Cancer Cell.
Last month, the university and GlaxoSmithKline announced a new research alliance.
Scientists from both parties will work together to identify new drug therapy opportunities and collaborate on projects.

